Library Screening
To fully understand how candidate antibodies interrupt cellular and molecular processes that lead to disease states, researchers need powerful tools that deliver multifactorial results.
NEW INFOGRAPHIC
Challenges and Solutions for Developing New Monoclonal Antibodies
Unprecedented advances in medicine are delivering remarkable results for some patients. Recent approvals of CAR T therapies and new approaches in regenerative medicine, for example, exemplify Monoclonal antibodies (mAbs) used for immunotherapy stimulate the immune system to mount a response to target antigens. These powerful therapeutics are being used to...
WEBINAR
Accelerating Nanobody Discovery Workflows with High-Throughput Flow Cytometry
In this webinar, Dr. Pieter Kennis discusses how nanobodies – small, single-domain antibody fragments that retain full antigen-binding capabilities and the properties of heavy-chain antibodies – and nanobody discovery and screening platforms exploit high-throughput flow cytometry to increase the throughput of nanobody screening campaigns.
Intellicyt® iQue3
Discover how the iQue3, the fastest suspension-based, high-throughput screening system available, is used to perform multiplexed screens for antibody binding to either cell surface or circulating target antigens.
Antibody Screening
Successful antibody discovery programs need to rapidly identify and characterize target-reactive candidates. The Intellicyt® iQue Screener PLUS platform can be used for target cell line generation, mouse sera evaluation and hybridoma library screening.
Advantages:
- Speed: More answers in less time
- More cost savings: Less sample volume and reagent costs
- Multiplexed assays: Rapid access to antibody specificity and species cross-reactivity during primary screening with multiplexed cell- and bead-based antibody binding assays.
Target Cell Line Generation
Rapidly evaluate clones transfected with a cell-surface target antigen. Selection of healthy clones that express high levels of the target antigen ensures optimal performance in downstream hybridoma screens.